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Experimental work and initial clinical experience support low-potassium dextran
solutions as lung perfusates. We have previously shown a protective effect of
prostaglandin E1 on ischemia-reperfusion injury in lung transplantation by a shift
from proinflammatory to anti-inflammatory cytokines in a rat lung transplantation
model. In this study, we tested the hypothesis that the addition of a prostacyclin
analog (iloprost) to low-potassium dextran might lead to improved surfactant and
ultimately graft function.
Methods: In a randomized, blinded study with a porcine left single-lung transplan-
tation model, donor lungs were flushed with 1 L of either low-potassium dextran
solution or low-potassium dextran solution modified by the addition of 250 g
iloprost (n  6 in each group). Grafts were stored at 4°C for 24 hours. After
transplantation, the right bronchus and pulmonary artery were clamped, and the
animals remained dependent on the graft. Posttransplantation graft function was
assessed throughout a 7-hour observation period by measuring oxygenation (30-
minute intervals), different pulmonary and systemic hemodynamic parameters, and
wet/dry lung weight ratios. Bronchoalveolar lavage fluid was obtained before and 2
hours after reperfusion. Surfactant function was measured from bronchoalveolar
lavage fluid with a pulsating bubble surfactometer. Neutrophil sequestration was
assessed by a myeloperoxidase assay performed on lung tissue specimens taken at
the end of the observation period.
Results: Pulmonary vascular resistance remained lower in the iloprost group than in
the control group (P  .05). Tissue water content after 7 hours of reperfusion
remained lower in the iloprost group (P  .05). In addition, significantly reduced
myeloperoxidase tissue activity was observed in the iloprost group (P  .05).
Although there was no difference in degradation of surface active surfactant large
aggregates to small aggregates, the surface tension measured at minimal bubble
diameter was lower in the iloprost group (P  .05).
Conclusions: Modification of low-potassium dextran solution with the prostacy-
clin analog iloprost resulted in a significant amelioration of ischemia-reperfu-
sion injury and improved preservation of surfactant function in transplanted
lungs. This intriguing approach merits further evaluation with respect to the
mechanisms involved and, ultimately, potential introduction into clinical lung
transplantation.
ascular Surgery ● January 2005
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TSIschemia-reperfusion (IR) injury is a major cause oflife-threatening primary graft dysfunction in ap-proximately 10% to 20 % of patients after lungtransplantation.1 In addition, obliterative bronchi-olitis is increasingly believed to be the result ofabnormal healing processes triggered by IR injury
and immunologic responses against the graft. This theory is
supported by the fact that major histocompatibility complex
class II molecules are upregulated in posttransplantation
pulmonary IR injury.2,3 Crocetti and coworkers4 have de-
scribed a possible relationship between the severity of post-
transplantation lung IR injury and the development of oblit-
erative bronchiolitis.
Many strategies of lung procurement have been devel-
oped and applied worldwide, with no concrete consensus
regarding which is the most effective.5 Safe graft ischemic
times are generally considered to be around 6 to 8 hours,
irrespective of which technique is used, suggesting that
none is superior to the others for short-term preservation of
good quality donor organs. Low-potassium dextran solution
(LPD) has been evaluated in experimental studies thor-
oughly during the past decade6-8 with superior results and
has been successfully introduced into clinical lung trans-
plantation by us and others.9,10 We strive continually for
further improvement. The ability to preserve the more mar-
ginal donor lungs with confidence could potentially increase
the pool of suitable donor organs.
Members of the prostanoid family have been shown to be
beneficial in improving graft function when added to pres-
ervation solutions such as Euro-Collins or University of
Wisconsin.11,12 Euro-Collins is an intracellular-type preser-
vation solution, with high potassium concentrations that
may cause vasoconstriction. The beneficial effect of iloprost
therefore previously was attributed to its vasodilatory prop-
erty, which probably leads to a better distribution of pres-
ervation solution throughout all parts of the lung graft. In
addition, prostanoids may promote pulmonary protection by
stimulating cyclic 3=,5=-adenosine monophosphate (cAMP)–
dependent protein kinase during cold ischemia; cAMP-
dependent protein kinase has been shown to reduce endo-
thelial permeability and to prevent neutrophil adhesion and
platelet aggregation.13 We have recently shown in a small-
animal model that prostaglandin (PG) significantly im-
proves lung function relative to the already superior lung
preservation associated with LPD by a shift from proinflam-
matory to anti-inflammatory cytokines.14 The protective
effect was achievable either by administration of the drug to
the flush solution or by continuous intravenous administra-
tion throughout the reperfusion period. The protective effect
of PGE1 was partially attributed to its vasodilatory property,
which reduces shear stress injury in lung grafts.15 However,
other vasodilatory agents did not have similar effects when
administered continuously during the reperfusion period
The Journal of Thoracafter lung ischemia.16 Prostanoids and their derivatives
therefore clearly have additional cytoprotective benefits on
lung grafts through mechanisms that remain largely un-
known.
The primary purpose of this study was to determine
whether iloprost, when administered in the preservation
solution, improves lung function and ameliorates IR injury
in the transplanted lung in a preclinical, large-animal, sin-
gle-lung transplantation model. Secondarily we sought to
determine whether such improvement was associated with
improved preservation of surfactant function in the graft
after the entire lung preservation, transplantation, and reper-
fusion process.
Material and Methods
Experimental Groups
Pigs were randomly divided into two groups of 6 animals each. In
the iloprost group, lungs were preserved with LPD (Perfadex;
Vitrolife, Göteborg, Sweden) plus 250 g/L of iloprost (Ilomedin;
Schering AG, Berlin, Germany) with the antegrade flush perfusion
technique. In the control group, lungs were flushed with LPD only
with the same flushing technique.
Surgical Preparation
Donor animal procedure. Female pigs (25-30 kg) were anes-
thetized with sodium pentobarbital (10 mg/kg) and fentanyl (1
mg/kg followed by a fentanyl infusion of 1 mg · kg1 · h1). The
animals were intubated and ventilated with 100% oxygen (inspira-
tory/expiratory ratio of 1:1, positive end-expiratory pressure of 5
mm Hg) in pressure-controlled mode with a maximum airway
pressure of 20 mm Hg and a ventilation rate of 10 breaths/min. A
median sternotomy was performed, and the pericardium was cut
open. A catheter to infuse preservation solution was inserted into
the main pulmonary artery. Heparin (3 mg/kg) was administered
intravenously. Cardiac arrest was induced by clamping of the
aorta, and cardioplegic solution was infused into the aortic root.
The venae cavae were clamped. Thereafter the left atrial auricle
was incised, and flush perfusion of the pulmonary artery was
induced. In 10 minutes 1000 mL of LPD or LPD plus iloprost was
administered at a temperature of 8°C. Ventilation of the lungs was
maintained throughout the entire flushing procedure. The heart and
lungs were excised en bloc. Care was taken to clamp the main left
bronchus, leaving the lung in a mildly inflated state. The left lung
was isolated from the heart-lung-block with a generous atrial cuff
and full lengths of both pulmonary arteries and main bronchus.
The lung was stored at 4°C in LPD for 24 hours.
Transplantation procedure. Female pigs (25-30 kg) were
anesthetized with sodium pentobarbital (10 mg/kg) and fentanyl (1
mg/kg followed by a fentanyl infusion of 1 mg · kg1 · h1). The
animals were intubated and ventilated with 50% oxygen (inspira-
tory/expiratory ratio of 1:1, positive end-expiratory pressure of 5
mm Hg) in pressure-controlled mode with a maximum airway
pressure of 20 mm Hg and a ventilation rate of 10 breaths/min. A
Swan-Ganz catheter (Baxter Healthcare Corporation CardioVas-
cular Group, Irvine, Calif) and a catheter to monitor arterial
pressure were placed into the right internal jugular vein and carotid
artery, respectively. A further catheter for monitoring extravascu-
ic and Cardiovascular Surgery ● Volume 129, Number 1 81
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TSlar lung water and intrathoracic total blood volume was inserted
into the right femoral artery. A left thoracotomy in the fifth
intercostal space was performed, and the pericardium was opened.
The left pulmonary artery, the tracheal bifurcation, and the pul-
monary veins were dissected. Umbilical tapes were applied to the
right and left pulmonary arteries and the right main bronchus. A
heparin dose of 300 IE/kg was administered intravenously. After
clamping of the left main bronchus and the left pulmonary artery,
the left pulmonary veins were ligated. Pneumonectomy of the left
lung was performed. A clamp was placed to the left atrium to close
the left pulmonary veins. The upper and lower pulmonary veins
were incised with the atrial tissue between those to open an atrial
cuff. Ventilation was continued, and the donor lung was implanted
starting with a bronchial end-to-end anastomosis with 4-0 polypro-
pylene running suture. Anastomosis of the left atrial cuff of the
donor lung with the recipient’s left atrial cuff was performed,
followed by completion of the left pulmonary artery end-to-end
anastomosis with 4-0 polypropylene running sutures. Immediately
before reperfusion, the graft vasculature was deaired by retrograde
perfusion. The pulmonary artery was declamped, and the graft was
ventilated. After 15 minutes of reperfusion, the right pulmonary
artery and main right bronchus were clamped. Experiments were
terminated by means of a pentobarbital overdose after 7 hours of
reperfusion.
Measurements of Lung Function, Extravascular Lung
Water, and Total Intrathoracic Blood Volume
In all experiments, atrial, systemic arterial, and pulmonary arterial
pressures were recorded on-line. Dynamic lung compliance was
monitored continuously with a modified ventilator (Dräger, Lü-
beck, Germany). Arterial blood gas analysis was performed after
placement of catheters and every 30 minutes during the reperfu-
sion period. At these intervals, pulmonary vascular resistance
(PVR) was calculated after measurement of cardiac output by
means of the transfemoral thermodilution catheter, which was
connected to the cardiac index (CI) computer (PICCO; Pulsion
Medical Systems AG, Munich, Germany). After calibration by
injection of cold 0.9% saline solution into the jugular vein, the
system calculated CI online by pressure curve analysis.17 By
means of the same thermal bolus injection that was distributed into
intravascular blood volume and extravascular lung water, the ex-
travascular lung water index (arithmetic value divided by body
weight in kilograms) was computed.18 For wet/dry ratios, speci-
mens were taken at the same site of pulmonary grafts to achieve
most comparable conditions.
Surfactant Analysis
Bronchoalveolar lavage fluid was obtained with 100 mL of 0.9%
saline solution from the right lower lobe in each donor for baseline
measurements. A second bronchoalveolar lavage, of the left lower
lobe, was performed after 2 hours of reperfusion. A differential
cell count was carried out to determine the number of polymor-
phonuclear leukocytes as a percentage of the total cell count. The
lavage fluid was immediately centrifuged at 150g, and the cell-free
supernatant was frozen at 80°C. Pellet and supernatant were
separated at 48,000g for 60 minutes. Protein and phospholipid
contents were determined. Phospholipids in the small aggregate
(SA)–containing supernatant and in the large aggregate (LA)–
containing pellet were determined by phosphorus analysis, and
82 The Journal of Thoracic and Cardiovascular Surgery ● Januathese contents were expressed in the SA/LA weight ratio. The
surfactant pellet was resuspended in saline solution supplemented
with calcium chloride (1.5 mmol/L). Surfactant function was de-
termined with a pulsating bubble surfactometer (Electronetics Inc,
Buffalo, NY). According to the technique described by Enhorn-
ing,19 40 mL of LA suspension, adjusted to a phospholipid con-
centration of 1 mg/mL, was analyzed. The surface tension at
minimal bubble size (min) was obtained after 5 minutes of bubble
pulsation at a rate of 20 cycles/min and a temperature of 37°C.
Before bubble pulsation was started, adsorption was determined as
surface tension 10 seconds after formation of a bubble. All analog
data were digitized and recorded on a personal computer.
Myeloperoxidase Activity Assay
Lung tissue was assayed for myeloperoxidase (MPO) activity, an
index of polymorphonuclear neutrophil sequestration, according to
the method of Suzuki and coworkers.20 MPO activity was assessed
at 37°C by monitoring the change in absorbance at 655 nm through
a 3-minute period in a COBAS FARA II centrifugal analyzer
(Roche Diagnostics Corporation, Laboratory Systems, Indianapo-
lis, Ind). The reaction mixture contained 16-mmol/L 3,3=,5,5=-
tetramethylbenzidine dissolved in N,N-dimethlyformamide in
0.22-mol/L phosphate buffer that contained 0.11-mol/L sodium
chloride at pH 5.4. The reaction was initiated by the addition of
3-mmol/L hydrogen peroxide. One unit of activity was defined as
a change of 1 unit in absorbance per minute at 37°C. Protein
contents of samples was determined by the bicinchoninic acid
protein assay system (Pierce Chemical Company, Rockford, Ill).
MPO activity is expressed as units per milligram of protein.
Animal Care
All animal received human care in compliance with the “Principles
of Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” (http://www.nap.edu/catalog/5140.html).
Statistical Analysis
All data are expressed as mean  SD. Continuous data were
analyzed by repeated measures analysis of variance. For data
without repeated measurement, analysis of variance was applied.
Data obtained from the 2 animals that died during the observation
period were included in statistical analyses up to the point at which
death occurred. All data were analyzed with SPSS software (SPSS
for MS Windows, version 11.5; SPSS Inc, Chicago, Ill).
Results
Donor and recipient pigs were matched for size in each
study group. The mean PaO2 levels in arterial blood in donor
animals in each group were not different. Two of the 6
recipient animals in the control group died during the reper-
fusion period from right heart failure at 2.5 and 4 hours after
initiation of reperfusion. All animals in the iloprost group
survived for the entire observation period.
Iloprost and Posttransplantation Lung IR Injury
After completion of the 7 hours of reperfusion, a mild trend
toward higher PaO2 levels was seen in the iloprost group
ry 2005
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mm Hg). However, this trend did not reach statistical sig-
nificance. PVR was significantly lower in the iloprost group
with time throughout the observation period than in the
control cohort (P  .05). Figure 1 illustrates the changes in
PVR with time in both groups throughout the 7-hour reper-
fusion period. Pulmonary arterial pressure, CI, and ex-
travascular lung water content were all not statistically
different between groups; however, trends toward lower
pulmonary arterial pressures (P  .1), increased CI (P 
.09), and less extravascular lung water content (P  .06)
were observed in the iloprost group. In addition, wet/dry
lung weight ratios were significantly lower at the end of the
reperfusion period in the iloprost group than in the control
group (P .05). Figure 2 shows wet/dry weight ratios at the
end of the reperfusion period.
Neutrophil sequestration in lung grafts was examined by
determination of MPO activity in lung tissue. As depicted in
Figure 3, MPO activity was significantly lower at the end of
the reperfusion period in the iloprost group than in the
control group (P  .05).
Effect of Iloprost on Surfactant Function and Alveolar
Surface Tension
Surfactant function was determined with a pulsating bubble
surfactometer. The analysis of surfactant function revealed
low minimal surface tension in donor lungs, considered as
baseline measurements for healthy lungs. After 2 hours of
reperfusion, a significant increase in surface tension (P 
.05) was seen in the iloprost group, as shown in Figure 4.
Although significantly different from baseline, values of
min of 3 mN/m indicate a good preservation of surfactant
function by iloprost. Lungs preserved with LPD without
iloprost (control) reached higher values of min (6  2
mN/m) than seen the iloprost group, indicating a slight to
moderate surfactant dysfunction. The SA/LA ratio was at a
low level in right donor lungs (baseline measurements)
before graft retrieval (Figure 5). After 2 hours of reperfu-
Figure 1. Changes in PVR with time in iloprost (Ilomedin) and
control groups throughout 7-hour reperfusion period.sion, a tremendous increase of SA/LA-ratio, suggesting
The Journal of Thoracsurfactant aggregate conversion, was observed. The SA/LA-
ratio was lower in the iloprost group than in the control
group, but the difference was not statistically significant (P
 .08). The protein content of the bronchoalveolar lavage
fluid revealed a tendency towards higher values after reper-
fusion in both groups. However, this finding did not reach
statistical significance (P  .2).
Discussion
IR injury remains a significant problem in lung transplan-
tation, leading to life-threatening graft dysfunction in ap-
proximately 10% to 20 % of recipients after transplanta-
tion.1,21 Evidence from this study and from previous
experiments by us and others suggests that prostanoids
improve lung function when administered intravenously
during the reperfusion period.14,15,22
We used a pig single-lung transplantation model of IR
injury to evaluate the protective effects of iloprost as an
additive to the lung preservation solution. We found that the
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Figure 2. Wet/dry lung weight ratios in iloprost (Ilomedin) and
control groups.
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Figure 3. MPO activities in lung grafts in iloprost (Ilomedin) and
control groups.addition of iloprost to the pulmonary flush solution (LPD)
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tion oxygenation ability, decreased PVR and pulmonary
arterial pressure, improved surfactant function, decreased
postreperfusion lung graft edema, improved cardiac output,
and decreased neutrophil sequestration in the graft during
reperfusion and after 7 hours of reperfusion. This model has
proved useful in our previous studies of interventions to
protect against IR injury after lung transplantation.23 We
preserved the lungs for an extended period of 24 hours to
ensure that we had sufficiently severely injured lungs. We
chose to examine the severity of the IR injury 7 hours after
the start of reperfusion because this corresponds to a time
point in the clinical setting when we frequently see evidence
of this injurious process.
The protective mechanisms of iloprost as an additive to
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Figure 4. Surface tension (min) in iloprost (Ilomedin) and control
groups and in right donor lungs before retrieval (baseline).
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Figure 5. SA/LA ratio in iloprost (Ilomedin) and control groups 2
hours after reperfusion and in right donor lungs before graft
retrieval (baseline). Asterisk indicates P < .05 versus two study
groups.the lung graft flush solution on IR injury, particularly on
84 The Journal of Thoracic and Cardiovascular Surgery ● Januasurfactant preservation and posttransplantation function, are
unknown and have not been studied previously. However,
Puskas and associates24 have speculated that a possible
protective effect of PGE1 on posttransplantation lung func-
tion could be seen in a beneficial effect on surfactant me-
tabolism. Indeed, in this study we observed a significant
improvement of posttransplantation surfactant function in
the iloprost group relative to the control lungs. The im-
proved surfactant function is represented by reduced mini-
mal alveolar surface tension and a trend toward lower
SA/LA ratios.23,25,26 The prevention of surfactant dysfunc-
tion in our study was associated with decreased IR injury in
the transplanted lungs, as assessed by standard physiologic
parameters commonly used in studying IR lung injury,
including PVR, pulmonary arterial pressure, CI, oxygen-
ation index (PaO2/inspired oxygen fraction ratio), wet/dry
lung tissue weight ratio, and lung compliance.6,14,23
The underlying mechanisms by which iloprost improves
lung preservation, and consequently posttransplantation
lung and surfactant functions, are not clear. We observed an
increase of the SA/LA ratio in both groups after reperfusion,
indicating an inactivation of surfactant, most likely by
plasma proteins leaking into the alveolar space. However,
other parameters of lung edema, such as wet/dry weight
ratio, revealed a reduction of capillary leakage with iloprost.
One therefore would expect a reduction in the SA/LA ratio
with iloprost. In this study, however, such a significant
reduction of surfactant inhibition could not be shown.
Another hypothesis regarding how iloprost might protect
surfactant function is the protection of type II cells by
reduction of an inflammatory response during the early
phase of reperfusion. The observed reduction of the myelo-
peroxidase activity in lung tissue may support this hypoth-
esis. This mechanism is of utmost importance, because its
consequences are not limited to the early posttransplantation
period but may also have impact on long-term graft func-
tion. Because it is known that surfactant function is im-
proved in the follow-up of all recipients, one should focus
on the prevention of type II cell injury during preservation
and reperfusion.
We have previously shown that a significant number of
lung graft cells undergo apoptosis during the very early
phase after clinical lung transplantation, with most being
type II cells.27 Surfactant function is associated with the
degree of type II and endothelial cell integrity, as shown by
Novick and colleagues.28 Because an antiapoptotic effect of
prostanoids has been described, we quantified the amount of
apoptosis and further examined the expression of the anti-
apoptotic gene Bcl-2 in our previous study on the effect of
PGE1 on posttransplantation rat lung function.14 We were
unable to show either a decrease of the number of apoptotic
cells or a significant upregulation of Bcl-2, but we found a
significant shift from proinflammatory to anti-inflammatory
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ceived PG intravenously during the 2-hour reperfusion pe-
riod. This underlines that prostanoids and other agents in-
creasing cAMP inhibit the production of several cytokines,
such as interleukin (IL) 12, tumor necrosis factor , and
IL-1.29 The underlying mechanism seems to be the down-
regulation of the action of nuclear factor B. In contrast to
these cytokines, IL-10 gene transcription is regulated by the
family of cAMP-responsive nuclear factors.30 Thus prosta-
noids may directly downregulate tumor necrosis factor 
and IL-12 and upregulate IL-10 from inflammatory cells,
such as macrophages and dendritic cells.
The lung collectin surfactant protein-A has both anti-
inflammatory and prophagocytic activities. Borron and co-
workers31 have previously shown that surfactant protein-A
inhibits the macrophage production of tumor necrosis factor
 stimulated by the gram-negative bacterial component
lipopolysaccharide.31 From these findings, one might spec-
ulate that improved lung preservation by iloprost leads to
improved posttransplantation surfactant function as a result
of preservation of the surfactant’s own ability to inhibit the
release of proinflammatory cytokines by alveolar macro-
phages in the transplanted lung. Iloprost could minimize the
posttransplantation proinflammatory response and ulti-
mately might influence the development of bronchiolitis
obliterans. This promising pathway has not been studied yet
and will be investigated in greater detail in our laboratory in
the future.
In summary, iloprost in the flush solution in a pig single-
lung transplantation model decreased the severity of IR
injury, as demonstrated by a trend toward improvements in
oxygenation, hemodynamics, and posttransplantation pul-
monary edema. Further, the amelioration of IR injury was
associated with improved surfactant preservation and post-
transplantation function. We were unable to ascertain the
mechanism responsible for the beneficial effects seen, but
that was not the aim of this study. Our attention should turn
toward the previously described shift from a proinflamma-
tory to an anti-inflammatory response to iloprost in lung
preservation and transplantation and its relationship to im-
proved surfactant preservation on posttransplantation lung
injury. Our ultimate goal is to be able to apply this simple
modification of lung preservation solutions to the clinical
setting to improve lung function after transplantation.
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